Frameshifts with Benjamin Arya
Benjamin Arya
0
Frameshifts with Benjamin Arya is a podcast spotlighting the world's most ambitious biotech founders, investors, researchers, and change-makers. Each episode features in-depth conversations with leaders driving innovation in biotechnology and related fields. The show explores the journeys, insights, and challenges of those shaping the future of biology and medicine. It aims to inspire and inform listeners interested in the cutting edge of biotech.
Episodes
-
Lucas Mair on AI, Robotics, and the Future of Fully Automated Biology | Frameshifts Episode #15 31.08.2026 1h 27mThis week, my X feed exploded with news that Anthropic had released hardware standards that allow AI agents to operate lab equipment directly. Their new “Model Hardware Standard” or MHS, built in collaboration with the Howard Hughes Medical Institute, allows an LLM to operate microscopes, liquid handlers, robotic arms and dozens of other instruments that scientists use to conduct experiments and to build the future.Until now, there has been no standard way to connect an LLM to a physical instrument. Every time you want to connect two pieces of equipment together, you need to create a bespoke i... -
Logan Thrasher Collins: The Trojan Horse That Could Fix Gene Therapy | Frameshifts Episode #14 05.07.2026 57mOn this show, we’ve talked a lot about gene editors. These are little molecular machines derived from or inspired by the Nobel-prize winning CRISPR system that put gene editing on the radar of the general public.Once these editors get into a cell, they can cut out DNA, change the DNA sequence, insert entire copies of genes or delete faulty genes that cause illness. Think of them as tools to cut, paste, backspace and overwrite the code of life.But the primary challenge with these gene editors, besides off-target edits and low-but-steadily-improving editing efficiencies, is that they need to get... -
Joe Betts-LaCroix on Retro, Reprogramming, and the First Real Longevity Drugs | Frameshifts Episode #13 20.06.2026 1h 21mMost longevity talk is still stuck within two bad schools of thought. On one side, weak-sauce incrementalism: supplements, vibes and tiny effect sizes. On the other, immortality rhetoric that asks you to throw out the data altogether. Joe Betts-LaCroix has very little patience for either.He’s the co-founder and CEO of Retro Biosciences, one of the most ambitious longevity companies in the world. Launched with an initial $180 million of capital from Sam Altman’s personal wealth, the company has since raised new round led by 4P Capital at a $1.8 billion valuation. Retro’s mission is to add ten h... -
Alex Zhavoronkov: Beating Aging, Designing Drugs and Betting on China | Frameshifts Episode #12 24.05.2026 1h 20mPlenty of people will tell you AI is about to design our drugs. Alex Zhavoronkov already has. His company’s lead candidate, rentosertib, is the first drug with both its biological target and its molecule discovered by generative AI to post real Phase 2 results in humans. That gap, between the pitch deck and a drug in an actual person, is the whole reason this conversation is worth your time.Alex started out in GPUs and high-performance computing, then left to bet that AI could design drugs better than people can. He retrained in biomedical science, and nearly two decades on, his company Insili... -
Building Science's Missing Infrastructure — Adam Marblestone | Frameshifts Episode #11 02.04.2026 1h 25mMany of science’s most important projects fall through the cracks between academia and industry. These are the foundational tools that could accelerate entire fields, and yet don’t fit neatly into a PhD thesis or a venture-backed startup.And to humanity’s credit, there has been growing interest in the last few years in building alternative systems for accelerating science beyond academia and industry.Groups like Episteme, the Arc Institute and Astera differ in structure and ambition, but they share a common premise: some of the most important work in science requires institutions that neither... -
Why 92% of Your Proteins Are Invisible — Parag Mallick | Frameshifts Episode #10 17.12.2025 1h 17mParag Mallick is a Stanford Professor and Chief Scientist at Nautilus Biotechnology, a publicly traded biotech company. He’s also a professional magician and circus performer, which might sound random until you realize that his company does the closest thing to proteomics magic I’ve ever seen. The things that make you weird, he argues, are exactly what let you see data differently than anyone else.Here’s what caught me off guard: we can only measure ~8% of human proteins with current mass spectrometry tools. The other 92%—what Parag calls the “dark proteome”—is essentially invisible to us.Why... -
Building the Wyss Institute, Organs-on-Chips, and Fighting for Science — Don Ingber | Frameshifts Episode #9 02.12.2025 1h 16mThe future of human biology isn’t about better animal models - it’s about building human organs on chips that think like the body does.Don Ingber, founding director of Harvard’s Wyss Institute, has one of the most unconventional origin stories in the field. In 1975, as a Yale undergrad, he took a sculpture class where students built floating structures held together only by tension; no rods touching, no rigid frames. At the same time, he watched cells in culture flatten, round up, and then flatten again.The connection clicked: cells aren’t rigid blocks; they’re dynamic tensegrity structures, g... -
Shelby Newsad: Why Platforms Fail, What Founders Need, and Where Biotech Wins | Frameshifts Episode #8 25.11.2025 1h 6mThis week, I sat down with Shelby Newsad, Partner at Compound VC, to break down what makes a great biotech investment and why so many platform stories fall short.Shelby lays out a playbook forged across therapeutics, diagnostics, and lab automation. We dive into why mechanistic understanding predicts success, how diagnostics evolve into data businesses, and why the next wave of value may come from closed loop automated labs that combine hardware and software to finally link the whole bench.We explore faster paths to human evidence through compassionate use, phase 0 trials, and cassette microdo... -
Space Travel, AI, and Immortality — Peter Diamandis | Frameshifts Episode #7 18.11.2025 1h 11mWhat happens when the man who launched commercial spaceflight decides humanity needs to stop aging?Peter Diamandis is building the infrastructure to tackle aging. He founded the XPRIZE Foundation, created Singularity University with Larry Page and Ray Kurzweil, and wrote the playbook on exponential thinking with Abundance and Bold. However, somewhere between flying Stephen Hawking into zero gravity and recruiting Elon Musk to his board, he realized something: if we’re building an unlimited future, we need to be around to see it.We talk about why Peter walked away from space (his first love) to... -
Minimally Invasive Neurosurgery, Brain-Computer Interfaces, and Continuous Pupil Monitoring — Theodore Schwartz 11.11.2025 1h 25mWhat happens when one of the world’s leading neurosurgeons steps away from the operating room to become a first-time founder? Dr. Theodore Schwartz pioneered minimally invasive brain surgery going through the nose and eyelid instead of opening the skull. He’s published over 200 papers, written a bestselling book on neurosurgery history, and now he’s building a MedTech startup to solve a problem that’s plagued him for decades: there’s no way to continuously monitor a patient’s pupils during surgery.This conversation goes deep. We talk about the psychological weight of knowing you might paralyze... -
Michael Florea: Smart Cages, AAV Cocktails & The Future of Longevity Research | Frameshifts Episode #5 04.11.2025 1h 21mThis week, I sat down with genome engineering prodigy Michael Florea.I first met Michael at the Longevity Biotech Fellowship retreat in Tahoe National Forest, California (2.5hrs east of SF). I was in the final days of building an AI edtech startup, and looking for advice on what to do next.Michael had been genetically engineering longevity since he was 16 years old. What he always wanted to do was extend the human lifespan. But he decided that the most impactful technology he could work on first was to remove the human bottleneck on in vivo experiments, namely for mice.In vivo experiments are... -
Virtual Cells, Programmable Biology, and the Quest to Hack Human Aging — Omar Abudayyeh & Jonathan Gootenberg 09.10.2025 1h 24mThis week, I sat down with Omar Abudayyeh and Jonathan Gootenberg, the co-PIs who helped pioneer the field of genome engineering, and are now leading one of the most innovative and productive bioengineering labs in the world.Omar and Jonathan met as graduate students in the lab of CRISPR pioneer, Feng Zhang. They have since co-authored more than 30 breakthrough papers that helped transform CRISPR-Cas from a basic research tool into a clinically relevant therapeutic and diagnostic modality. Their work has led to the founding of companies like Sherlock Biosciences, Proof Diagnostics, and Tome Bi... -
Francisco LePort & Martin Borch Jensen: The Biotech Founders Testing 25 Drugs in One Horse | Frameshifts Episode #3 01.10.2025 1h 21mIn this week’s episode, I sit down with Francisco LePort and Martin Borch Jensen, the co-founders of Gordian Biotechnology. Gordian is revolutionizing drug discovery by testing where it matters most… directly in living organisms. We discuss their groundbreaking approach of pooled in vivo screening that transforms a single organism into thousands of parallel experiments, and how this could fundamentally change our approach to studying age-related diseases.Francisco and Martin believe that traditional anti-aging drug discovery has been ignoring the biology of aging itself. Instead of testing dru... -
Ron Weiss: Building Biological Neural Networks to Fight Cancer | Frameshifts Episode #2 24.09.2025 1h 18mIn this week's episode, I sit down with Prof. Ron Weiss, the MIT pioneer who helped create the field of synthetic biology. We discussed the emergence of living therapeutics that can think, adapt, and make complex decisions inside the human body. The implications of this stretch from synthetic cells within implantable biosensors that can produce insulin based on real-time glucose sensing to self-amplifying RNAs encoding gene circuits that specifically detect and kill cancer cells.Ron believes the future of medicine lies in treating biological systems as sophisticated analog computers… systems w... -
Kevin Esvelt: Sculpting Evolution, Engineered Viruses and Safeguarding Biotechnology | Frameshifts Episode #1 11.09.2025 1h 21m“What I wanted to do was harness evolution as effectively as possible.”In this episode, I sit down with pioneering synthetic biologist Kevin Esvelt. Together, we explore how technologies like gene drives and phage-assisted continuous evolution could help tackle humanity’s toughest challenges, from eradicating malaria to protecting global food security. We also dig into the urgent need to safeguard biotechnology against misuse.This is a conversation about the future of science, biosecurity, and society, and how we can harness biology safely to create a healthier, more equitable world.🔔 SUBSCRI... -
Eldin Rostom: Biotech Entrepreneurship and Becoming a Dad | Insane Ambition Episode #14 18.07.2024 1h 22mForbes 30 Under 30 honoree, Eldin Rostom, CEO and Co-Founder of Diag-Nose.io, who is pioneering the way forward in the diagnosis of chronic nasal disorders. In this episode, Eldin recounts his journey from participating in the MedTech Actuator Accelerator to being one of the select Australian companies to enter the Creative Destruction Lab in Seattle. This episode explores how Diag-Nose.io employs AI to improve diagnostic accuracy for ENT specialists by analysing biological protein profiles, directly addressing the problem of antibiotic over-prescription.Eldin also shares the personal motivati... -
Joe Foster: Founding Reebok & Building a Globally Recognised Brand | Insane Ambition Episode #13 04.07.2024 1h 4mMeet Joe Foster, founder of Reebok, who revolutionised the sportswear industry by building a multi-billion dollar shoe empire. In this episode, Joe recalls his earliest memories of war, shares stories of his grandfather the cobbler, and recounts founding Reebok as a competitor to his father's inherited shoe brand, eventually growing it into a billion-dollar empire.This episode delves into Joe's philosophies and the "why" behind his success, exploring the strategies and mindset that drove Reebok's rise and providing valuable insights into the world of high-stakes business and brand building.Don... -
Ethan Donati: From Social Anxiety to hosting the World's Top Speakers | Insane Ambition Episode #12 20.06.2024 52mIn this episode, we sit down with Ethan Donati, a marketing expert who overcame social anxiety to host some of Australia's largest events. Ethan shares his journey from a shy individual to a prominent event organiser, detailing the challenges and strategies involved in bringing top speakers like Gary Vee and David Goggins to Australia. Tune in as he discusses the nuances of event planning, the importance of personal branding, and key marketing principles that drive success. Subscribe now on Apple Podcasts, Spotify, and YouTube for exclusive conversations with industry leaders driving innovatio... -
Michael Batko: Rethinking Startups & Shaping Tomorrow's Tech Giants | Insane Ambition Episode #11 06.06.2024 55mStep into the world of startup transformation with Michael Batko, the visionary CEO behind Startmate. With a track record of nurturing 230+ startups valued at over $2 billion, Startmate is a catalyst for entrepreneurial success.Join us as we unravel Michael's journey from consulting to traversing the Amazon rainforest to leading the future of Australia’s startup ecosystem. Don't miss this insightful episode on Insane Ambition! Subscribe now on Apple Podcasts, Spotify, and YouTube for exclusive conversations with industry leaders driving innovation in technology.#startup #technology #innovation... -
Jane Gunn: Future of Australia’s Health System & Primary Care Crisis | Insane Ambition Episode #10 23.05.2024 1h 9mJoining us is the inaugural chair of Primary Care Research at Royal Melbourne Hospital, Jane Gunn. Known not only as a medical practitioner and PhD graduate, Jane is also the Dean of the Faculty of Medicine at Australia's top-ranked medical school, The University of Melbourne. In this episode, we'll delve into her thoughts on the future of Australia's public health system, the role of innovative technologies, the effects of COVID-19 on the educational system, and the evolving landscape of medical education and research. Tune in to Insane Ambition on Apple Podcasts, Spotify, and YouTube for thi...
Popular in
The podcast also appears in the podcast charts of these countries.